Wang Tian, Zhang Fulin, Zhang Peirong
Department of Oncology Hematology, Yan'an People's Hospital, Yan'an, Shaanxi 716000, P.R. China.
Department of Pathology, Yantian District People's Hospital, Shenzhen, Guangdong 518000, P.R. China.
Exp Ther Med. 2023 May 9;25(6):304. doi: 10.3892/etm.2023.12003. eCollection 2023 Jun.
Breast cancer is a common malignant tumor in women. Increasing evidence has demonstrated that nuclear receptor coactivator 5 (NCOA5) and targeting protein for xenopus kinesin-like protein 2 (TPX2) serve vital roles in the progression of breast cancer. However, to the best of our knowledge, the molecular mechanisms underlying the involvement of TPX2/NCOA5 in the development of breast cancer are not fully understood at present. In the present study, the expression levels of NCOA5 and TPX2 were compared between paired non-tumor and tumor tissues of patients with breast cancer using the TNMplot tool. Expression differences of NCOA5 and TPX2 in human breast epithelial cell lines (MCF10A and MCF12A) and human breast cancer cell lines (MCF7 and T47D) were assessed via reverse transcription-quantitative PCR and western blotting. Additionally, proliferation, migration and invasion of breast cancer cells were determined via Cell Counting Kit-8, would healing and transwell assays. angiogenesis was determined using a tube formation assay. Furthermore, TPX2 was identified as a high-confidence NCOA5 interactor based on BioPlex network data sets. A co-immunoprecipitation assay was adopted to confirm the interaction between TPX2 and NCOA5. The present study revealed that TPX2 and NCOA5 were highly expressed in breast cancer cells. TPX2 interacted with NCOA5 and there was a positive association between TPX2 and NCOA5 expression. NOCA5 knockdown repressed the proliferation, migration, invasion and angiogenesis of breast cancer cells. In addition, TPX2 knockdown suppressed the proliferation, migration and invasion of breast cancer cells, and inhibited angiogenesis, and all of these effects were reversed following NCOA5 overexpression. In conclusion, NCOA5 was a downstream target of TPX2 in enhancing proliferation, migration, invasion and angiogenesis of breast cancer cells.
乳腺癌是女性常见的恶性肿瘤。越来越多的证据表明,核受体共激活因子5(NCOA5)和非洲爪蟾驱动蛋白样蛋白2靶向蛋白(TPX2)在乳腺癌进展中发挥着重要作用。然而,据我们所知,目前TPX2/NCOA5参与乳腺癌发生发展的分子机制尚未完全明确。在本研究中,使用TNMplot工具比较了乳腺癌患者配对的非肿瘤组织和肿瘤组织中NCOA5和TPX2的表达水平。通过逆转录定量PCR和蛋白质印迹法评估NCOA5和TPX2在人乳腺上皮细胞系(MCF10A和MCF12A)及人乳腺癌细胞系(MCF7和T47D)中的表达差异。此外,通过细胞计数试剂盒-8、伤口愈合试验和Transwell试验检测乳腺癌细胞的增殖、迁移和侵袭能力。使用管腔形成试验检测血管生成。此外,基于BioPlex网络数据集,TPX2被鉴定为高可信度的NCOA5相互作用分子。采用免疫共沉淀试验证实TPX2与NCOA5之间的相互作用。本研究表明,TPX2和NCOA5在乳腺癌细胞中高表达。TPX2与NCOA5相互作用,且TPX2与NCOA5表达之间呈正相关。敲低NCOA5可抑制乳腺癌细胞的增殖、迁移、侵袭和血管生成。此外,敲低TPX2可抑制乳腺癌细胞的增殖、迁移和侵袭,并抑制血管生成,而NCOA5过表达后所有这些作用均被逆转。总之,在增强乳腺癌细胞的增殖、迁移、侵袭和血管生成方面,NCOA5是TPX2的下游靶点。